Amantadine ER (Gocovri/ADS-5102) vs AV-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: NMDA receptor · full Parkinson's Disease pipeline
Amantadine ER (Gocovri/ADS-5102)
Marketed by Supernus Pharmaceuticals and partners
NCT02136914 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 126 participants, with 63 assigned to ADS-5102 and 63 to placebo. The primary clinical endpoint was met: the week-12 UDysRS score decreased by 15.9 points with ADS-5102 versus 8.0 points with placebo, with a between-group difference of -7.9 points (p=0.0009).
Reported efficacy
Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score (Baseline to Week 12): Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score (Baseline to Week 12): ADS-5102 (Amantadine HCl Extended Release) -20.7 units on a scale (Standard Error 2.2) vs Placebo -6.3 units on a scale (Standard Error 2.08) (met)
Result source: NCT02274766
AV-101
Developed by VistaGen Therapeutics
NCT04147949 · Phase 2 · status unknown
This is a small, randomized, double-blind, placebo-controlled crossover study using a validated dyskinesia rating scale as its primary measure. Results have not yet been posted, so the grade reflects only the well-controlled design in a modest number of participants.
No aligned efficacy figure on record for this race.
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Amantadine ER (Gocovri/ADS-5102) | AV-101 |
|---|---|---|
| OFF time, change | —Not reported | —Not reported |
| ON time without troublesome dyskinesia, change | 3.6 vs 0.9+2.7 vs placeboNCT013974222 other results
| —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- Amantadine ER (Gocovri/ADS-5102)
- —Not reported
- AV-101
- —Not reported
ON time without troublesome dyskinesia, change
- Amantadine ER (Gocovri/ADS-5102)
- 3.6 vs 0.9+2.7 vs placeboNCT01397422
2 other results
- 3.8 vs 0.9 NCT01397422
- 4.1 vs 0.9 NCT01397422
- AV-101
- —Not reported
UPDRS Part III, change
- Amantadine ER (Gocovri/ADS-5102)
- —Not reported
- AV-101
- —Not reported
MDS-UPDRS Part II, change
- Amantadine ER (Gocovri/ADS-5102)
- —Not reported
- AV-101
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AV-101: no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Amantadine ER (Gocovri/ADS-5102): 4 of 4 rows · AV-101: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Amantadine ER (Gocovri/ADS-5102) |
|---|---|
| Dropout rate | 33.3%340 mga NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 11 more results40%420 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 14.3%340 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 15%260 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 23.7% NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 —Full Dose NCT04387773 · Phase 4 · registry result, not featured evidence —Half Dose NCT04387773 · Phase 4 · registry result, not featured evidence —Half Dose NCT04387773 · Phase 4 · registry result, not featured evidence 47.4%Group 1P NCT02202551 · Phase 3 · registry result, not featured evidence 41.7%Group 1a NCT02202551 · Phase 3 · registry result, not featured evidence 41.7%Group 2 NCT02202551 · Phase 3 · registry result, not featured evidence 36.1%Group 3 NCT02202551 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —340 mga NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 11 more results40%420 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 14.3%340 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 15%260 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 2.6% NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 —Full Dose NCT04387773 · Phase 4 · registry result, not featured evidence —Half Dose NCT04387773 · Phase 4 · registry result, not featured evidence —Half Dose NCT04387773 · Phase 4 · registry result, not featured evidence 24.4%Group 1P NCT02202551 · Phase 3 · registry result, not featured evidence 13.3%Group 1a NCT02202551 · Phase 3 · registry result, not featured evidence 20.8%Group 2 NCT02202551 · Phase 3 · registry result, not featured evidence 14.8%Group 3 NCT02202551 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 11.1%340 mga NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 11 more results20%420 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 0%340 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 5%260 mg NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 10.8% NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 0%Full Dose NCT04387773 · Phase 4 · registry result, not featured evidence 0%Half Dose NCT04387773 · Phase 4 · registry result, not featured evidence 0%Half Dose NCT04387773 · Phase 4 · registry result, not featured evidence 26.9%Group 1P NCT02202551 · Phase 3 · registry result, not featured evidence 26.7%Group 1a NCT02202551 · Phase 3 · registry result, not featured evidence 25%Group 2 NCT02202551 · Phase 3 · registry result, not featured evidence 27.9%Group 3 NCT02202551 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 340 mga hallucination, any type 28.6% (placebo 1.7%) hallucination, visual 23.8% (placebo 1.7%) oedema peripheral 23.8% (placebo 0%) NCT02136914 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 11 more results420 mg constipation 15% (placebo 9.1%) dizziness 15% (placebo 4.5%) fall 15% (placebo 13.6%) NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 340 mg dizziness 28.6% (placebo 4.5%) constipation 23.8% (placebo 9.1%) dry mouth 19% (placebo 0%) NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 260 mg constipation 35% (placebo 9.1%) dizziness 15% (placebo 4.5%) dry mouth 15% (placebo 0%) NCT01397422 · Phase 2/3 · monotherapy · Parkinson's Disease · phase 2/3 dry mouth 13.5% (placebo 2.6%) nausea 13.5% (placebo 2.6%) decreased appetite 10.8% (placebo 0%) NCT02274766 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 Full Dose urinary retention 16.7% dry mouth (xerostomia) 0% orthostatic hypotension 0% NCT04387773 · Phase 4 · registry result, not featured evidence Half Dose dry mouth (xerostomia) 12.5% orthostatic hypotension 12.5% urinary retention 0% NCT04387773 · Phase 4 · registry result, not featured evidence Half Dose dry mouth (xerostomia) 0% orthostatic hypotension 0% urinary retention 0% NCT04387773 · Phase 4 · registry result, not featured evidence fall 37.2% hallucination (pooled) 30.8% hallucination, visual 30.8% NCT02202551 · Phase 3 · registry result, not featured evidence hallucination (pooled) 25% hallucination, visual 23.3% fall 21.7% NCT02202551 · Phase 3 · registry result, not featured evidence fall 37.7% edema peripheral 19.7% hallucination (pooled) 16.4% NCT02202551 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Amantadine ER (Gocovri/ADS-5102)
show 1 more result
show 1 more result
show 3 more results
show 2 more results
show 2 more results
show 35 more results
show 3 more results
show 3 more results
show 27 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amantadine ER (Gocovri/ADS-5102)'s landscape · AV-101's landscape